SynthesisCNS drugs2020
Psychedelic Treatments for Psychiatric Disorders: A Systematic Review and Thematic Synthesis of Patient Experiences in Qualitative Studies.
Synthesis in CNS drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.
- Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.Journal of psychopharmacology (Oxford, England) · 2022Pooled it
- Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.Psychopharmacology · 2022Pooled it
- Efficacy and Safety of Four Psychedelic-Assisted Therapies for Adults with Symptoms of Depression, Anxiety, and Posttraumatic Stress Disorder: A Systematic Review and Meta-Analysis.Journal of psychoactive drugsPooled it
- Mapping the phenomenology of intranasal 5-MeO-DMT in psychedelic-naïve healthy adults.Scientific reports · 2025Trial
- Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study.Scientific reports · 2024Trial
- Understanding experiences of psychedelic treatments for eating disorders: a meta-synthesis of qualitative studies.BMC medicine · 2026Review
- Facing trauma under the influence of psychedelics: A phenomenological study with Nova rave survivors.Journal of psychopharmacology (Oxford, England) · 2026Article
- The science of psychedelic medicine.Nature medicine · 2026Review
- The therapeutic role of self-transcendence in moral injury recovery:Frontiers in psychiatry · 2026Article
- Psychedelic-assisted therapy: a survey on the clinical methods of Swiss physicians.Therapeutic advances in psychopharmacology · 2026Article
- Lived experience as systems-relevant evidence in psychedelic public health.Frontiers in public health · 2026Article
- Case Report: Amplified psychoanalysis? Psychoanalysis, OCD and MDMA in a clinical case study.Frontiers in psychology · 2026Article
- Body image phenomenology in reports of psychedelic and meditative experiences: main themes and associations with body attitudes.Neuroscience of consciousness · 2026Article
- Article
- Comparing psychedelic and meditation experience reports with natural language processing.Scientific reports · 2025Article
- Psychedelics in the Treatment of Neurologic and Psychiatric Disorders: Coincidence or a New Point of View.Molecular neurobiology · 2025Review
- Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.Journal of eating disorders · 2025Article
- Exploring Self-Reported Effects of Naturalistic Psychedelic Use Among Gender and Sexual Minorities: A Quantitative Survey Study.Journal of psychoactive drugs · 2025Article
- Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa.Journal of eating disorders · 2025Article
- A prospective ecological momentary assessment study of an ayahuasca retreat: exploring the salutary impact of acute psychedelic experiences on subacute affect and mindfulness skills in daily life.Psychopharmacology · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionInterest in the use of psychedelic substances for the treatment of mental disorders is increasing. Processes that may affect therapeutic change are not yet fully understood. Qualitative research methods are increasingly used to examine patient accounts; however, currently, no systematic review exists that synthesizes these findings in relation to the use of psychedelics for the treatment of mental disorders.
objectiveTo provide an overview of salient themes in patient experiences of psychedelic treatments for mental disorders, presenting both common and diverging elements in patients' accounts, and elucidating how these affect the treatment process.
methodsWe systematically searched the PubMed, MEDLINE, PsycINFO, and Embase databases for English-language qualitative literature without time limitations. Inclusion criteria were qualitative research design; peer-reviewed studies; based on verbalized patient utterances; and a level of abstraction or analysis of the results. Thematic synthesis was used to analyze and synthesize results across studies. A critical appraisal of study quality and methodological rigor was conducted using the Critical Appraisal Skills Programme (CASP).
resultsFifteen research articles, comprising 178 patient experiences, were included. Studies exhibited a broad heterogeneity in terms of substance, mental disorder, treatment context, and qualitative methodology. Substances included psilocybin, lysergic acid diethylamide (LSD), ibogaine, ayahuasca, ketamine and 3,4-methylenedioxymethamphetamine (MDMA). Disorders included anxiety, depression, eating disorders, post-traumatic stress disorder, and substance use disorders. While the included compounds were heterogeneous in pharmacology and treatment contexts, patients reported largely comparable experiences across disorders, which included phenomenological analogous effects, perspectives on the intervention, therapeutic processes and treatment outcomes. Comparable therapeutic processes included insights, altered self-perception, increased connectedness, transcendental experiences, and an expanded emotional spectrum, which patients reported contributed to clinically and personally relevant responses.
conclusionsThis review demonstrates how qualitative research of psychedelic treatments can contribute to distinguishing specific features of specific substances, and carry otherwise undiscovered implications for the treatment of specific psychiatric disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.